Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to investigate the 5cm^2 and 10cm^2 doses of rivastigmine
transdermal patch in terms of efficacy and safety in patients with probable Alzheimer's
Disease (MMSE [Mini Mental State Examination] 10-20). A 52-week extension phase evaluated the
safety and tolerability of long-term treatment by rivastigmine transdermal patch in patients
with probable Alzheimer's Disease (AD).